newsfilter
← Latest News
GlobeNewswire·

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b